Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.it

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, November 22, 2024-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September...

Notice of AGM

DXS INTERNATIONAL PLC(AQSE: DXSP)Notice of 2024 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that its Annual General Meeting is scheduled to take place on Thursday 19 thDecember at Noon at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB.For further information in relation to the AGM,...

Pharmaceutical Waste Management Market Analysis: Innovations Driving Sustainable…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-34A1606/Global_Pharmaceutical_Waste_Management_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-34A1606/Global_Pharmaceutical_Waste_Management_Market Major Factors Driving the Growth of Pharmaceutical Waste Management Market: The pharmaceutical waste management market is witnessing robust growth due to the increasing generation of waste from drug production, healthcare...

Global Ceramic Ball Valve Market Analysis (2024-2030): Resilient Solutions for…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-5S9269/Global_Ceramic_Ball_Valve_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-5S9269/Global_Ceramic_Ball_Valve_Market Major Factors Driving the Growth of Ceramic Ball Valve Market: The ceramic ball valve market is growing as industries recognize their durability, chemical resistance, and efficiency in demanding applications. Key factors driving growth include their...

Inventiva reports 2024 Third Quarter Financial Information¹

Cash and cash equivalents at €13.9 million, as of September 30, 2024.Revenues of €1.3 million for the first nine months of 2024.On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 2024 2and the receipt of the $10 million milestone payment under the amended license and collaboration agreement...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; November 21, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the...

Zero Candida Announces TSX Venture Exchange Listing Date

About Zero Candida About Zero Candida Zero Candida is focused on commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor. ZC technology is a combination of a therapy light source with a selected wavelength and intensity and a transparent gel-based drug delivery system to maintain the optimum Ph level in the vagina. The device when used...

Embrace Sustainable Luxury: LILYSILK's Black Friday Delivers Discount on…

"LILYSILK is more than just elegance; we advocate a lifestyle of respect and care for our natural world," said David Wang, CEO of LILYSILK. "Our products surpass aesthetic appeal to fulfill the rising demand for high-quality, ethically and sustainably produced goods. This Black Friday, we invite our customers to select items that showcase their refined taste and dedication to environmental stewardship. LILYSILK's textiles allow consumers to enjoy both comfort and a positive impact…

Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial

180 enrolled patients ensures that at least 170 evaluable patients will be included in the planned early readout. This earlier readout is expected around March 2026 and is designed to provide the foundation for a potential BLA submission under the FDA's accelerated approval pathway. Recruitment efforts for the DIAGNODE-3 trial will continue to ensure comprehensive data collection from the full trial cohort of approximately 330 patients that will be followed for a total of 24 months. 180...

Acies Bio and Protein Evolution Announce Strategic Partnership to Advance…

Protein Evolution, a pioneer in enzyme-driven plastics recycling, has announced a collaboration withAcies Bio, an innovative biotechnology company specializing in microbial R&D and biomanufacturing. This partnership aims to leverage Acies Bio's state-of-the-art SmartRoute ™ platform to scale the production of Protein Evolution's plastic-degrading enzymes, bringing the world one step closer to a future free from plastic waste.Through the SmartRoute ™ platform, Acies Bio will...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial…

uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy ( MTLE ).“The dosing of the first patient in our Phase I/II trial in temporal lobe epilepsy represents an important milestone for uniQure and our third clinical trial initiation over the past...

Zymeworks Announces Participation in Upcoming Investor Conferences

Piper Sandler 36 thAnnual Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and present on December 3 at 1:30 pm Eastern Time (ET) in New York, NY.Citi's 2024 Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a panel discussion titled: 'Novel Antibody Mechanisms in Oncology' on December 3 at 3:15 pm ET in Miami, FL.7 thAnnual Evercore HealthCONx Conference: Zymeworks' management will participate in...

Outcomes4Me and the National Comprehensive Cancer Network (NCCN) Expand…

BOSTON, Nov. 21, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first direct-to-patient, personalized, and evidence-based cancer navigation platform, and the National Comprehensive Cancer Network® (NCCN®) announced today that Outcomes4Me has newly integrated the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer into its free, consumer-grade, direct-to-patient platform. BOSTON , Nov. 21, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer...

H.I.G. Capital Announces the Sale of Deenova S.r.l.

Since its initial investment, H.I.G. has supported Deenova's international growth through strategic acquisitions and the strengthening of its management team. The Company has become an industry leader throughout Europe, with a current presence in approximately 100 hospitals in Italy, France, United Kingdom, Malta, Germany, Spain, and Poland. Since its initial investment, H.I.G. has supported Deenova's international growth through strategic acquisitions and the strengthening of its management...

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of…

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial$25M milestone payment to be received from Jazz Pharmaceuticals in relation to the FDA approval; Zymeworks remains eligible for up to $500M in...

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

"The launch of MSK-IMPACT® powered with SOPHiA DDM™ is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine," said Philippe Menu, M.D., PhD., Chief Product Officer and Chief Medical Officer, SOPHiA GENETICS. "Following the successful launch of MSK-ACCESS® powered with SOPHiA DDM™ earlier this year, we are incredibly excited to further build on our excellent collaboration with…

3Shape A/S and Medit Corp. Reach Settlement in Patent Infringement Lawsuit

"3Shape is pleased to have resolved this matter and move forward without further litigation," said Henriette Stakemann, 3Shape General Counsel. "Our focus remains on protecting our intellectual property while continuing to innovate and deliver value to our customers." "3Shape is pleased to have resolved this matter and move forward without further litigation," saidHenriette Stakemann, 3Shape General Counsel. "Our focus remains on protecting our intellectual…

New Alliance for the Development of a Sublingual Oxytocin Formulation to Prevent…

This problem, characterized by excessive bleeding after childbirth, is one of the leading causes of maternal mortality worldwide, according to the World Health Organization (WHO). Currently, it is estimated to affect approximately 14 million women each year and causes around 70,000 deaths, mostly in low- and middle-income countries. With the implementation of this sublingual treatment, many lives could be saved and provide a practical and accessible solution for the management of postpartum…

Philips unveils next-generation BlueSeal helium-free MRI system, integrated with…

Industry's first wide bore, high-performance helium-free [1] 1.5T MR features AI assistance at every step in the MRI workflow, with seamless integration of cloud-based AI image reading and reporting tools on the MR scanner Philips BlueSeal helium-free magnet combined with compact and lightweight design allows flexibility of installations in difficult and remote locations to improve wider access to advanced MRIPhilips' award-winning [2] AI-based SmartSpeed image reconstruction...

Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution)…

Reporting of transactions made by persons discharging managerial…

COSRX Kicks Off Black Friday/Cyber Monday Sales with Up to 56% Off!

Bioretec signed a new sales and distribution agreement to accelerate the…

Orion Research Foundation grants EUR 1,109,000 for research in 2025

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Notice of AGM

Pharmaceutical Waste Management Market Analysis: Innovations Driving Sustainable…

Global Ceramic Ball Valve Market Analysis (2024-2030): Resilient Solutions for…

Inventiva reports 2024 Third Quarter Financial Information¹

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Zero Candida Announces TSX Venture Exchange Listing Date

Embrace Sustainable Luxury: LILYSILK's Black Friday Delivers Discount on…

Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial

Acies Bio and Protein Evolution Announce Strategic Partnership to Advance…

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial…

Zymeworks Announces Participation in Upcoming Investor Conferences

Outcomes4Me and the National Comprehensive Cancer Network (NCCN) Expand…

H.I.G. Capital Announces the Sale of Deenova S.r.l.

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of…

SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024

3Shape A/S and Medit Corp. Reach Settlement in Patent Infringement Lawsuit

New Alliance for the Development of a Sublingual Oxytocin Formulation to Prevent…

Philips unveils next-generation BlueSeal helium-free MRI system, integrated with…